11d • General discussion
How approved GLPS compare to such RUOs as Retatrutide
1) You can hit a “satiety ceiling,” so the difference you feel shrinks
Both tirzepatide and retatrutide activate GLP-1 pathways that reduce appetite via gut–brain signalling and central satiety circuits. Once someone has been on high-dose therapy, appetite and cravings may already be strongly suppressed (and eating patterns already adapted), so moving to another incretin drug may produce less noticeable incremental appetite change—even if weight loss continues. GLP-1 appetite effects are well-established and partly central (brain) and partly peripheral (GI).
Translation: if hunger is already “turned down to 2/10,” it’s hard to feel a new drug turning it down further—even if metabolism is changing.
2) The “fullness” sensation from slowed gastric emptying often attenuates with time
A big part of early appetite suppression on GLP-1–based therapy is slower gastric emptying (food stays in the stomach longer → earlier fullness). But multiple clinical and peri-operative reviews note that the gastric-emptying delay can attenuate with ongoing treatment (often framed as tachyphylaxis/attenuation), meaning the dramatic early “I can’t eat” feeling is less prominent later.
So if someone is coming from prolonged/high-dose tirzepatide, they may:
- already be adapted to the gastric-emptying effect, and
- perceive retatrutide as “less appetite suppressing,” even if it’s still effective.
(There is debate on how complete this attenuation is across drugs and measurement methods, but attenuation is commonly described clinically.)
3) Retatrutide’s extra weight effect isn’t only appetite — it likely adds energy expenditure via glucagon biology
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon receptors), unlike tirzepatide (GLP-1 + GIP).
That glucagon-receptor component is important because glucagon signalling can:
- increase energy expenditure/thermogenesis (context-dependent),
- increase fat oxidation and shift fuel use,
- counterbalance some of the metabolic “slow-down” that comes with weight loss.
This is one of the key scientific rationales for triple-agonism: you may get more fat loss per unit of appetite suppression compared with GLP-1/GIP alone.
Translation: people may not feel much more suppressed appetite, but their body may be burning more and partitioning fuel differently—so weight is still controlled.
4) Subjective appetite ≠ objective calorie intake (and tirzepatide can “rewire” ingestive behaviour)
Appetite is a subjective sensation, but weight change reflects the net of:
- energy intake,
- energy expenditure,
- nutrient partitioning,
- glycaemic variability and hunger rebounds,
- adherence and tolerability.
There’s evidence that tirzepatide changes ingestive behaviour and energy intake in controlled settings. After someone has already undergone those behavioural and neurohormonal changes, switching to retatrutide might not produce a dramatic new hunger signal reduction—yet weight can remain controlled through the metabolic mechanisms above plus ongoing satiety signalling.
5) Retatrutide’s clinical weight loss is large even when GI symptoms (often mistaken for “appetite suppression”) vary
In the phase 2 obesity trial, retatrutide produced very large mean weight loss (dose-dependent), and—as with this class—GI effects (nausea, vomiting, diarrhoea) were common. Many people unconsciously label nausea/food aversion as “appetite suppression.” If someone tolerated high-dose tirzepatide well (less nausea over time), they may experience retatrutide as “not suppressing appetite,” simply because they’re not getting that aversive overlay—even though the drug can still strongly impact body weight through other pathways.
A clean way to phrase it (scientific but understandable)
After high-dose tirzepatide, many people are already near a satiety ceiling and have adapted to the gastric-emptying effect that makes early GLP-1 therapy feel powerfully appetite-suppressing. Retatrutide still activates GLP-1 and GIP, but its additional weight effect likely comes from its glucagon-receptor activity, which can increase energy expenditure and fat oxidation. So the person may not feel markedly less hungry, yet they can still lose or maintain weight because the drug is shifting energy balance through metabolic pathways as well as appetite.
In summary, longterm use of GLPS can cause somewhat of a dependence on GLPs, which is why they should be used as a tool to support training, nutrition and lifestyle - not, the go to solution for weightloss.
Take a break from GLPs and let your body reset to its natural metabolic state, and then utilise GLPs as and when - short term use is key.
I cycle GLPS
GLPs are life
1
0 comments
How approved GLPS compare to such RUOs as Retatrutide
powered by
skool.com/thrivepeptiva-2860
Educational group on the benefits, optimisation and safe use of peptides. UK Based
Suggested communities
Powered by